In this webcast about early-stage Alzheimer disease, Drs Burke and Apostolova highlight important conversations to have with patients and their care partners on topics such as diet, exercise, driving, and plans for the later stage of illness.
This report describes carbamazepine level fluctuations that occurred concurrent with stopping and restarting of cannabis use in a patient with bipolar disorder.
Case reports suggest a link between obsessive-compulsive disorder (OCD) and dementia, but this association has received little research. The current study investigated dementia risk among OCD patients using a national health insurance research database.
Great strides in research on Alzheimer disease diagnostic biomarkers and treatment targets have taken place over the past 2 decades. Listen as Dr Goldfarb highlights exciting developments.
What are the steps for diagnosing Alzheimer disease? Are you familiar with diagnostic criteria and assessment tools? In this webcast, walk through the process with an expert.
What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical experience on these topics in this journal CME activity.
Although psychotherapy is available via the Veterans Health Administration, most veterans diagnosed with posttraumatic stress disorder (PTSD) receive pharmacotherapy. This study evaluated longitudinal prescription practice trends for veterans with PTSD.
This comprehensive meta-analysis informs clinicians and patients about the potential effectiveness of omega-3 fatty acids as add-on therapy for borderline personality disorder.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT